ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization
Panoramic ECGi to Guide Ablation of Non-Paroxysmal AF: Effect of Ibutilide on AF Source Location and Organization
Sponsor: Medtronic
Terminated
1 patient enrolled (consented) but screen failed. Study stopped as unable to enroll.
Other terminated trials from Medtronic
Other Atrial Fibrillation trials with similar outcome
This NA trial investigates Atrial Fibrillation and Persistent Atrial Fibrillation and is currently terminated or withdrawn. Medtronic leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
-
Jan 2021 — Dec 2022 [monthly]
Terminated NA
▶ Show 5 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Terminated NA
-
Feb 2020 — Mar 2020 [monthly]
Terminated NA
-
Sep 2018 — Feb 2020 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Jun 2018 — Sep 2018 [monthly]
Recruiting NA
-
Dec 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medtronic
- Vivek Reddy
For direct contact, visit the study record on ClinicalTrials.gov .